Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566395 · ClinicalTrials.gov registry record · Phase 3
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
A Phase 3 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT02566395 is a Phase 3 study that has completed, run by Northwell Health. The registered enrollment target is 10 participants.
The verdict
NCT02566395, a Phase 3 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
This clinical pilot trial is intended to evaluate the feasibility, efficacy and safety of hematopoietic stem cell transplantation (HSCT) from Human Leukocyte Antigen (HLA)-mismatched related donors for children and young adults with hematologic malignancies who lack a suitably matched related or unrelated donor. The methodology will be one that has been successfully utilized in adult patients at Thomas Jefferson University.
Interventions
- DRUG Cyclophosphamide
- RADIATION Radiation
- BIOLOGICAL Donor Lymphocyte Infusion (DLI)
- BIOLOGICAL Haploidentical Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12 |
| Est. Completion | 2022-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02566395
The ClinicalTrials.gov registry entry for NCT02566395 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02566395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02566395 about?
NCT02566395 is a clinical study titled "Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies". This clinical pilot trial is intended to evaluate the feasibility, efficacy and safety of hematopoietic stem cell transplantation (HSCT) from Human Leukocyte Antigen (HLA)-mismatched related donors for children and young adults with hematologic malignancies who lack a suitably matched related or unr...
What is the current status of trial NCT02566395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2014-12. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT02566395?
The interventions under investigation include: Cyclophosphamide (DRUG), Radiation (RADIATION), Donor Lymphocyte Infusion (DLI) (BIOLOGICAL), Haploidentical Stem Cell Transplantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT02566395?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.